Logo image
Incidence of lymphoma associated with underlying lupus: lessons learned from observational studies
Journal article   Peer reviewed

Incidence of lymphoma associated with underlying lupus: lessons learned from observational studies

Tanmayee Bichile and Michelle Petri
Current opinion in rheumatology, v 26(2), pp 111-117
01 Mar 2014
PMID: 24419748

Abstract

Life Sciences & Biomedicine Rheumatology Science & Technology
Purpose of reviewThe increased risk of overall malignancy in systemic lupus erythematosus (SLE) is well established. Cohort studies have shown a significant association of non-Hodgkin's lymphoma with SLE. This review will focus on the associated risk factors, the role of immunology, immunosuppressive medications and secondary Sjogren's syndrome in the development of lymphoma in SLE.Recent findingsCohort studies have established the link between non-Hodgkin's lymphoma and SLE. The largest study to date has been of 16409 patients from 30 rheumatologic centres. In the last decade, insights into the roles of BAFF (BLyS) and APRIL in lymphoma development have helped to understand the mechanism leading to monoclonality. Genetic markers have helped to prognosticate diffuse large B-cell lymphoma. The contribution of disease activity and immunosuppressive drugs in lymphoma development is still not understood in SLE.SummaryAlthough the association of non-Hodgkin's lymphoma in SLE is well established, risk factors attributing to this association are still not understood.

Metrics

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: SDGs in the Output

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Rheumatology
Logo image